JP2024544586A - Sert、dat、および/またはnet活性を調節するためのmdmaの類縁体 - Google Patents

Sert、dat、および/またはnet活性を調節するためのmdmaの類縁体 Download PDF

Info

Publication number
JP2024544586A
JP2024544586A JP2024529704A JP2024529704A JP2024544586A JP 2024544586 A JP2024544586 A JP 2024544586A JP 2024529704 A JP2024529704 A JP 2024529704A JP 2024529704 A JP2024529704 A JP 2024529704A JP 2024544586 A JP2024544586 A JP 2024544586A
Authority
JP
Japan
Prior art keywords
disorder
alkenyl
haloalkenyl
alkyl
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024529704A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544586A5 (cg-RX-API-DMAC7.html
Inventor
プレラ、グレン
ガンディー、マイケル
スカフィディ、エイドリアン
キング、ジャスミン
ピゴット、マシュー
Original Assignee
ジ ユニバーシティ オブ ウェスタン オーストラリア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021903836A external-priority patent/AU2021903836A0/en
Application filed by ジ ユニバーシティ オブ ウェスタン オーストラリア filed Critical ジ ユニバーシティ オブ ウェスタン オーストラリア
Publication of JP2024544586A publication Critical patent/JP2024544586A/ja
Publication of JP2024544586A5 publication Critical patent/JP2024544586A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024529704A 2021-11-26 2022-11-28 Sert、dat、および/またはnet活性を調節するためのmdmaの類縁体 Pending JP2024544586A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2021903836 2021-11-26
AU2021903836A AU2021903836A0 (en) 2021-11-26 Analogues
AU2022901261 2022-05-12
AU2022901261A AU2022901261A0 (en) 2022-05-12 Analogues
PCT/AU2022/051422 WO2023092195A1 (en) 2021-11-26 2022-11-28 Analogues of mdma for modulating sert, dat, and / or net activity

Publications (2)

Publication Number Publication Date
JP2024544586A true JP2024544586A (ja) 2024-12-03
JP2024544586A5 JP2024544586A5 (cg-RX-API-DMAC7.html) 2025-12-03

Family

ID=86538463

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024529704A Pending JP2024544586A (ja) 2021-11-26 2022-11-28 Sert、dat、および/またはnet活性を調節するためのmdmaの類縁体

Country Status (5)

Country Link
EP (1) EP4436964A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024544586A (cg-RX-API-DMAC7.html)
AU (1) AU2022399234A1 (cg-RX-API-DMAC7.html)
CA (1) CA3239040A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023092195A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
WO2022221415A2 (en) 2021-04-13 2022-10-20 The Regents Of The University Of California Tetracyclic compounds for treating brain disorders
JP2025502615A (ja) 2021-12-15 2025-01-28 デリックス セラピューティクス,インク. フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005154350A (ja) * 2003-11-26 2005-06-16 Japan Science & Technology Agency 不斉アリルアミンの合成方法
AU2004309067B2 (en) * 2003-12-23 2009-12-17 Basf Aktiengesellschaft 1-(azolin-2-yl) amino-1,2-diphenylethane compounds for combatting insects, arachnids and nematodes

Also Published As

Publication number Publication date
CA3239040A1 (en) 2023-06-01
WO2023092195A1 (en) 2023-06-01
EP4436964A4 (en) 2025-10-08
EP4436964A1 (en) 2024-10-02
AU2022399234A1 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
EP4436964A1 (en) Analogues of mdma for modulating sert, dat, and / or net activity
KR102615098B1 (ko) 시클로프로필 우레아 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
KR20230142817A (ko) 화합물
AU2002237654B2 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (CNS) disorders
CN108137508B (zh) 5-ht2c受体激动剂和组合物及使用方法
JP5281395B2 (ja) 統合失調症の治療用のglyt1阻害剤としてのシクロヘキサンスルホニル誘導体
JP2010508343A (ja) 薬理学的に活性なn,n’−置換型3,7−ジアザビシクロ[3.3.1]ノナン類、それらに基づく医薬組成物、及びそれらの使用方法
HRP940890A2 (en) Novel(r)-5-carbamoyl-8-fluoro-3-n,n-disubstituted-amino-3,4-dihydro-2h-1-benozpyranes
MX2011012712A (es) Derivados de carboxamida sustituidos con arilo como bloqueadores del canal de calcio o sodio.
JP6091716B2 (ja) オレキシン受容体アンタゴニストとしての(s)−(2−(6−クロロ−7−メチル−1h−ベンゾ[d]イミダゾール−2−イル)−2−メチルピロリジン−1−イル)(5−メトキシ−2−(2h−1,2,3−トリアゾール−2−イル)フェニル)メタノンの塩結晶形
CN109952301B (zh) 5-ht2c受体激动剂和组合物及使用方法
JP6751161B2 (ja) フッ素含有トリアゾロピリジン系化合物、その製造方法、医薬組成物及び用途
AU2014358742B2 (en) Crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
AU2002237654A1 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (CNS) disorders
CN102595893B (zh) 螺内酰胺衍生物及其用途
JP6483105B2 (ja) ピペラジン誘導体および医薬としてのその使用
CA3157843A1 (en) Modifier of four-membered ring derivative, preparation method and application thereof
JP2010523495A (ja) サブタイプ選択的アザビシクロアルカン誘導体
TW202333736A (zh) 稠合吡咯啶精神成形素(psychoplastogen)及其用途
CN115108986A (zh) 阿朴菲衍生物及其制备方法和应用
JP6831376B2 (ja) トリアゾール誘導体
JP2018531253A6 (ja) トリアゾール誘導体
JP2019509987A (ja) Eaat3阻害剤としてのピラゾール−ピリジン誘導体
JP2008503559A (ja) Cns障害を治療するためのピリジルピペラジン
KR20200060404A (ko) 신규한 염

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20240717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251125